Peripheral artery disease (PAD) is widely recognized as a manifestation of systemic atherosclerosis. However, the mechanisms responsible for symptomatic progression of femoropopliteal disease remain incompletely understood. Clinical experience suggests that lesion progression in the lower extremities often does not follow a predictable pattern based only on plaque burden or angiographic severity. Lesions that appear relatively stable may progress over short time intervals, distal runoff may deteriorate without obvious proximal disease progression, and procedural complications such as distal embolization remain unpredictable. These observations suggest that femoropopliteal PAD may be influenced by biological mechanisms different from disease progression in coronary artery disease. In a recent issue of The American Journal of Cardiology , Jinnouchi and colleagues provide important mechanistic insights using optical frequency domain imaging (OFDI), demonstrating that symptomatic femoropopliteal lesions are frequently characterized by acute thrombus and healed plaque.

PAD has historically been conceptualized as a progressive atherosclerotic disorder characterized by gradual plaque build-up and subsequent luminal narrowing. This concept assumes that thrombosis represents an episodic complication superimposed on progressive plaque growth. Increasing pathological and clinical evidence suggests that this concept may not fully explain disease progression in the femoropopliteal circulation. Histopathologic studies demonstrate the presence of important differences between peripheral and coronary artery disease, including greater fibrocalcific disease and less lipid-rich necrotic core in lower-extremity arteries. ^, Although the actual mechanisms of these differences are unclear, they likely reflect a unique biomechanical environment of the femoropopliteal segment, where repetitive flexion, torsion, and compression influence plaque development and vascular remodeling.

The relatively large diameter of femoropopliteal arteries permits substantial plaque burden to accumulate without producing clinically significant stenosis. As a result, isolated plaque growth may remain clinically silent until superimposed thrombus formation produces flow-limiting obstruction. The predominance of acute thrombus and healed plaque in symptomatic lesions observed by Jinnouchi and colleagues is consistent with this concept and suggests that thrombotic processes may contribute importantly to the development of clinically significant stenosis.

The frequent association between calcification and thrombus formation further highlights the distinct biology of femoropopliteal disease. In coronary arteries, thrombosis most commonly occurs in association with lipid-rich, vulnerable plaque rupture or erosion, whereas calcified nodules represent a smaller proportion of events. In contrast, extensive intimal and medial calcification is characteristic of PAD and is particularly common among patients with diabetes mellitus and chronic kidney disease. ^, Mechanical stress acting on heavily calcified arterial segments may contribute to plaque disruption and thrombus formation, which may subsequently organize into healed plaque and contribute to progressive luminal narrowing.

The high prevalence of healed plaque observed in femoropopliteal arteries supports the mechanism of subclinical thrombosis in PAD. Healed plaque suggests that recurrent thrombus formation may have been a contributory factor to lesion progression. A similar process has been described in coronary arteries, where repeated plaque disruption and healing contribute to progressive stenosis. Extension of this concept to femoropopliteal arteries provides a plausible explanation for the variable clinical course of PAD and the observation that lesion severity may change over relatively short intervals.

The relationship between thrombus-related lesion characteristics and distal runoff also deserves consideration. Progressive deterioration in tibial vessel patency is frequently observed in patients with advanced femoropopliteal disease. Although the mechanisms responsible for this pattern remain uncertain, distal embolization from thrombus-rich femoropopliteal lesions has long been considered a potential contributing factor. Mechanistic observations linking thrombus and impaired runoff provide support for this hypothesis and suggest that thrombus formation in the femoropopliteal segment may influence disease progression throughout the lower extremity.

Recognition of thrombotic processes as an important component of PAD may also help explain the clinical benefits observed with intensified antithrombotic therapy. In the COMPASS trial, low-dose rivaroxaban combined with aspirin reduced major adverse cardiovascular events and major adverse limb events in patients with PAD compared with aspirin alone, including a substantial reduction in major amputation. Similarly, in the VOYAGER PAD trial, rivaroxaban plus aspirin reduced acute limb ischemia and other limb events following lower-extremity revascularization. These findings suggest that thrombotic activity contributes to PAD progression and clinical events. Therefore, antithrombotic therapy may influence the underlying mechanism of distal lower extremity disease progression by reducing recurrent thrombus formation.

For the interventionalist, these observations highlight the limitations of angiography for understanding lesion biology. Angiography provides information regarding lumen dimensions but offers limited insight into plaque composition or thrombus burden. Lesions that appear angiographically stable may contain substantial thrombus or complex plaque architecture that may influence procedural risk and outcomes. Thrombus-containing lesions may be particularly susceptible to distal embolization during endovascular intervention, potentially contributing to slow-flow phenomena and deterioration in distal perfusion.

High-resolution intravascular imaging modalities such as OFDI or optical coherence tomography provide the ability to characterize lesion morphology in vivo and may improve understanding of femoropopliteal disease mechanisms. Although the routine and cost-effective use of these technologies in peripheral intervention remains uncertain, selective imaging in complex lesions may provide valuable mechanistic information. Future studies are needed to determine whether imaging-defined lesion characteristics using OFDI are associated with clinical outcomes such as restenosis, distal embolization, or limb events.

There are several limitations that should be considered when interpreting these mechanistic findings. The study is a single-center with a retrospective design and a relatively small number of patients. Chronic total occlusions were largely excluded, limiting generalizability to more advanced disease. In addition, some OFDI imaging was performed after balloon dilation, which may have influenced plaque morphology or thrombus characterization. Irrespective, the consistency of the observations provides useful insight into the mechanisms of progression of femoropopliteal arterial disease.

The observations reported by Jinnouchi and colleagues contribute to an improved understanding of symptomatic femoropopliteal PAD and highlight the importance of thrombotic processes in lesion progression. Symptomatic femoropopliteal disease appears to be the result of interaction between atherosclerotic plaque, calcification, and thrombus formation within a mechanically dynamic vascular environment. Future investigation needs to integrate intravascular imaging with clinical outcomes to further clarify the role of thrombus in PAD progression and to guide future therapeutic strategies.